Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients

Paul Haut, Susan Cohn, Elaine Morgan, Maureen Hubbell, Karina Danner-Koptik, Marie Olszewski, Mary Schaff, Morris Kletzel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume4
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Pediatrics
Drug Therapy
Blood Component Removal
Peripheral Blood Stem Cell Transplantation
Peripheral Blood Stem Cells
Platelet Count
Neoplasms
Leukemia
Neutrophils
Catheters
Bone Marrow
Morbidity
Transplants
Mortality
Therapeutics

Keywords

  • PBSC
  • Pediatrics
  • Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. / Haut, Paul; Cohn, Susan; Morgan, Elaine; Hubbell, Maureen; Danner-Koptik, Karina; Olszewski, Marie; Schaff, Mary; Kletzel, Morris.

In: Biology of Blood and Marrow Transplantation, Vol. 4, No. 1, 1998, p. 38-42.

Research output: Contribution to journalArticle

Haut, P, Cohn, S, Morgan, E, Hubbell, M, Danner-Koptik, K, Olszewski, M, Schaff, M & Kletzel, M 1998, 'Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients', Biology of Blood and Marrow Transplantation, vol. 4, no. 1, pp. 38-42.
Haut, Paul ; Cohn, Susan ; Morgan, Elaine ; Hubbell, Maureen ; Danner-Koptik, Karina ; Olszewski, Marie ; Schaff, Mary ; Kletzel, Morris. / Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. In: Biology of Blood and Marrow Transplantation. 1998 ; Vol. 4, No. 1. pp. 38-42.
@article{240e50546169472fb562e22c5a1a460b,
title = "Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients",
abstract = "Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.",
keywords = "PBSC, Pediatrics, Transplant",
author = "Paul Haut and Susan Cohn and Elaine Morgan and Maureen Hubbell and Karina Danner-Koptik and Marie Olszewski and Mary Schaff and Morris Kletzel",
year = "1998",
language = "English (US)",
volume = "4",
pages = "38--42",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients

AU - Haut, Paul

AU - Cohn, Susan

AU - Morgan, Elaine

AU - Hubbell, Maureen

AU - Danner-Koptik, Karina

AU - Olszewski, Marie

AU - Schaff, Mary

AU - Kletzel, Morris

PY - 1998

Y1 - 1998

N2 - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

AB - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

KW - PBSC

KW - Pediatrics

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0031610287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031610287&partnerID=8YFLogxK

M3 - Article

C2 - 9701390

AN - SCOPUS:0031610287

VL - 4

SP - 38

EP - 42

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -